In an attempt to improve the outcome of Ph+ ALL, a chemotherapy-free approach consisting of dasatinib and corticosteroids followed by two cycles of blinatumomab, a bi-specific T-cell engager antibody that recruits T cells to CD19+ B-cells, was recently investigated in a phase 2 clinical trial of newly diagnosed Ph+ ALL patients [70]. Here, CD19 is linked to acute lymphoblastic leukemia.